CO
Coward_Nutlick
Community Contributor
Member since 2025
Views1.3kTotal number of views
Followers24Total number of followers
Comments0Total number of comments
Subscribers0Total number of subscribers
Former Silicon Valley Biotech Venture Capitalist
No link added
Very Bullish
98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more
719
users have viewed this narrative5users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
CO
US$100
89.4% undervalued intrinsic discount
Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2031
US$140.1
Very Bullish
It is almost impossible to obtain a drug label from the FDA for pediatric use - this topical non-steroidal drug ZORYVE is very safe and highly effective for both pediatric and adult patients. The drug is potent in the skin, it is not well absorbed and is quickly metabolized which limits systemic exposure and minimizes side effect risks.Read more
560
users have viewed this narrative4users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
CO
US$39.99
40.9% undervalued intrinsic discount
Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2030
US$55.82